Noema Pharma Gets Fast Track Status for Neuralgia Drug Candidate

Noema Pharma has received FDA’s Fast Track designation for basimglurant for treatment of patients with trigeminal neuralgia, a condition that includes pain from the trigeminal nerve in the front part of the head.

The FDA previously approved the company’s Investigational New Drug Application for a phase 2/3 clinical trial which is now enrolling participants. The treatment was safe and well-tolerated in adult subjects and effective in controlling pain in multiple animal models of neuropathic pain, the company said.

The FDA grants Fast Track status to expedite the review of drugs for treating serious conditions and that fill an unmet medical need.